STUDIES ON THE REGULATION OF PROTEIN CONCENTRATIONS IN “RED” AND “WHITE” SKELETAL MUSCLES**This work was supported by research grants from the National Institutes of Health (GM-23045) and from the Muscular Dystrophy Association.

Author(s):  
Herbert G. Lebherz ◽  
Marialyn J. Sardo ◽  
James K. Petell ◽  
Janis E. Shackelford
1964 ◽  
Vol 207 (6) ◽  
pp. 1451-1451
Author(s):  
Robert M. Dowben ◽  
Leon Zuckerman ◽  
Paul Gordon ◽  
Stephen P. Sniderman

Page 1049: Footnotes 3 and 4 for authors Paul Gordon and Stephen P. Sniderman, respectively, should be transposed to read, for Paul Gordon: Fellow of the MEDRA Foundation. Present address: Dept. of Pharmacology, Chicago Medical School, Chicago 12, Ill. For Stephen P. Sniderman: Trainee in Metabolism under National Institutes of Health Training Grant 2A-5071. Present address: University of Michigan Hospital, Ann Arbor, Mich.


2020 ◽  
Author(s):  
Thomas Taetzsch ◽  
Dillon Shapiro ◽  
Randa Eldosougi ◽  
Tracey Myers ◽  
Robert Settlage ◽  
...  

AbstractDuchenne muscular dystrophy (DMD) is characterized by progressive degeneration of skeletal muscles. To date, there are no treatments available to slow or prevent the disease. Hence, it remains essential to identify molecular factors that promote muscle biogenesis since they could serve as therapeutic targets for treating DMD. While the muscle enriched microRNA, miR-133b, has been implicated in the biogenesis of muscle fibers, its role in DMD remains unknown. To assess the role of miR-133b in DMD-affected skeletal muscles, we genetically ablated miR-133b in the mdx mouse model of DMD. In the absence of miR-133b, the tibialis anterior muscle of juvenile and adult mdx mice is populated by small muscle fibers with centralized nuclei, exhibits increased fibrosis, and thickened interstitial space. Additional analysis revealed that loss of miR-133b exacerbates DMD-pathogenesis partly by altering the number of satellite cells and levels of protein-encoding genes, including previously identified miR-133b targets as well as genes involved in cell proliferation and fibrosis. Altogether, our data demonstrate that skeletal muscles utilize miR-133b to mitigate the deleterious effects of DMD.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Nizar Y. Saad ◽  
Mustafa Al-Kharsan ◽  
Sara E. Garwick-Coppens ◽  
Gholamhossein Amini Chermahini ◽  
Madison A. Harper ◽  
...  

AbstractFacioscapulohumeral muscular dystrophy (FSHD) is a potentially devastating myopathy caused by de-repression of the DUX4 gene in skeletal muscles. Effective therapies will likely involve DUX4 inhibition. RNA interference (RNAi) is one powerful approach to inhibit DUX4, and we previously described a RNAi gene therapy to achieve DUX4 silencing in FSHD cells and mice using engineered microRNAs. Here we report a strategy to direct RNAi against DUX4 using the natural microRNA miR-675, which is derived from the lncRNA H19. Human miR-675 inhibits DUX4 expression and associated outcomes in FSHD cell models. In addition, miR-675 delivery using gene therapy protects muscles from DUX4-associated death in mice. Finally, we show that three known miR-675-upregulating small molecules inhibit DUX4 and DUX4-activated FSHD biomarkers in FSHD patient-derived myotubes. To our knowledge, this is the first study demonstrating the use of small molecules to suppress a dominant disease gene using an RNAi mechanism.


2000 ◽  
Vol 295 (3) ◽  
pp. 93-96 ◽  
Author(s):  
Takashi Kimura ◽  
Masanori P Takahashi ◽  
Yoshinobu Okuda ◽  
Misako Kaido ◽  
Harutoshi Fujimura ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document